Dianthus Therapeutics, Inc. (DNTH)
| Market Cap | 5.23B +247.6% |
| Revenue (ttm) | 1.90M -60.8% |
| Net Income | -192.25M |
| EPS | -4.11 |
| Shares Out | 55.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,187,399 |
| Open | 98.35 |
| Previous Close | 98.35 |
| Day's Range | 89.78 - 98.53 |
| 52-Week Range | 32.22 - 117.88 |
| Beta | 0.06 |
| Analysts | Strong Buy |
| Price Target | 140.80 (+50.69%) |
| Est. Earnings | Nov 4, 2026 |
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio... [Read more]
Financial Performance
In 2025, Dianthus Therapeutics's revenue was $2.04 million, a decrease of -67.35% compared to the previous year's $6.24 million. Losses were -$162.34 million, 91.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $140.8, which is an increase of 50.69% from the latest price.
News
Dianthus files automatic mixed securities shelf
16:03 EDT Dianthus (DNTH) files automatic mixed securities shelf
Dianthus initiated with an Overweight at JPMorgan
JPMorgan analyst Brian Cheng initiated coverage of Dianthus (DNTH) with an Overweight rating and $135 price target Dianthus is a clinical-stage biotech developing therapeutics for severe autoimmune di...
Dianthus Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Claseprubart has delivered robust clinical results in MG and CIDP, prompting accelerated trial timelines and strategic trial design changes. The pipeline is expanding with DNTH212 and DNTH312, targeting broader neuromuscular and autoimmune markets, while CIDP and MMN represent significant growth opportunities.
Dianthus Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
Significant pipeline progress was highlighted, with positive clinical data for claseprubart in MG and CIDP, and key MMN results expected soon. The company is well-positioned in competitive neuromuscular markets, advancing early-stage assets, and has a strong cash runway into 2030.
Dianthus initiated with a Buy at Citi
Citi analyst Samantha Semenkow initiated coverage of Dianthus (DNTH) with a Buy rating and $156 price target The company is developing “best-in-class” therapies for severe autoimmune diseases, the ana...
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
Dianthus Therapeutics to Participate in Three Investor Conferences During September
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
Dianthus price target raised to $128 from $110 at Truist
Truist raised the firm’s price target on Dianthus (DNTH) to $128 from $110 and keeps a Buy rating on the shares. Dianthus continues to advance its pipeline with DNTH312 expanding…
Dianthus price target raised to $158 from $130 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Dianthus (DNTH) to $158 from $130 and keeps a Buy rating on the shares. The firm says DNTH312 combines complement and B-cell…
Dianthus price target raised to $122 from $105 at Wedbush
Wedbush raised the firm’s price target on Dianthus (DNTH) to $122 from $105 and keeps an Outperform rating on the shares. While key development timelines remain on track for claseprubart,…
Dianthus reports Q2 EPS (90c), consensus (91c)
Reports Q2 revenue $761,000, consensus $248,750. “Our strong execution in the first half of 2026 reflects the continued focus and discipline of the Dianthus (DNTH) team as we advance both…
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic I...
Dianthus Therapeutics Earnings release: Q2 2026
Dianthus Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Dianthus Therapeutics Quarterly report: Q2 2026
Dianthus Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms D...
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus Therapeutics Slides: Corporate presentation
Dianthus Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus initiates EMERGE trial of claseprubart
Dianthus (DNTH) announced initiation of the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis. EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial in appr...
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28
Dianthus’ new CAPTIVATE responder rate beat expectations, says Raymond James
Raymond James reiterated a Strong Buy rating and $125 price target on Dianthus (DNTH) after the company reported data from Part A of its Phase 3 CAPTIVATE study evaluating claseprubart…
Dianthus reports additional data from Part A of CAPTIVITY study
In a regulatory filing, Dianthus (DNTH) Therapeutics reported more data from Part A of its Phase 3 CAPTIVTY study evaluating claseprubart in chronic inflammatory demyelinating polyneuropathy. The comp...
Dianthus price target raised to $132 from $110 at Jefferies
Jefferies raised the firm’s price target on Dianthus (DNTH) to $132 from $110 and keeps a Buy rating on the shares. The firm sees limited negative readthrough to Dianthus’ claseprubart…
